Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B
Bleeding severity in haemophilia usually correlates with the levels of circulating clotting factor. 1 Patients with mild (factor levels 6%-40% of normal activity) or moderate haemophilia (1%-5%)
bleed infrequently, predominantly due to trauma or after surgery, while individuals with severe disease (<1%) experience frequent spontaneous bleeding, particularly into joints and muscles, or after minor trauma. 1 In patients with haemophilia B, prophylaxis with factor IX (FIX) aims to maintain appropriate trough levels to reduce the incidence of bleeds. 1 In severe cases, lower trough levels are associated with an increase in total bleeding events and haemarthroses. an extended half-life compared with standard products, allowing a prolonged dosing interval. 3 The safety and efficacy of rIX-FP was demonstrated in adults/adolescents (7-, 10-and 14-day prophylaxis treatment regimens) and paediatrics (7-day prophylaxis only) in two phase III trials of previously treated patients (PTPs) with severe haemophilia B (FIX activity [FIX:C] ≤2%).
3,4
The aim of this analysis was to evaluate mean steady-state and observed trough FIX:C levels during prophylaxis with rIX-FP in these two clinical trials and to assess the impact of treatment with rIX-FP on patients with haemophilia B.
The detailed study designs of the adult/adolescent (NCT0101496274) and paediatric (NCT01662531) rIX-FP phase 3 studies have been described previously. rIX-FP delivers consistently high observed trough FIX:C levels with 7-and 14-day prophylaxis dosing regimens. These findings are consistent with the low median ABRs observed 3, 4 and suggest that by maintaining high trough FIX:C levels, rIX-FP effectively converts a patient with severe haemophilia B to a mild bleeding phenotype. The 7-and 14-day prophylaxis regimens, albeit at different dose ranges, result in FIX trough levels >10%, suggesting that in adult patients therapy can be individualized to suit a patient's lifestyle and requirements, depending on the trough level required.
One limitation of studying FIX trough levels is that FIX enters the extravascular space, and only plasma FIX:C levels can currently be measured. The extravascular space may act as a store for FIX; therefore, trough levels may not correlate directly with the amount of FIX present in tissues nor the ability of FIX to prevent bleeds. 5 In biodistribution studies, rIX-FP was detected in extravascular mineralized bone regions 120-240 hours postdose, whereas conventional recombinant FIX (rFIX) was not visible after 24 hours. 6 The excellent haemostatic efficacy of rIX-FP at extended dosing intervals may be due to the FIX stored in the extravascular space. 5 Further study of extravascular FIX and its association with FIX trough levels and bleeding rates is required.
Trough levels for other extended half-life products have been evaluated; however, studies between the products cannot be directly compared, due to differences in the study populations. An rFIX Fc fusion protein (rFIXFc; ALPROLIX ® , eftrenonacog alfa;
Biogen Idec, Inc, Cambridge, MA) produces a low ABR with prophylaxis every 1-2 weeks. 7 Dosing in clinical trials was designed to target trough levels of 1%-3%, 7 and lower bleeding rates were seen with increasing trough levels 2 ; however, steady-state trough 33 (156) 41 (230) 16 (83) 18 (106) 6 (13) 16 (27) 17 (30) 23 ( 37 (185) 45 (278) 16 (88) 18 (113) 8 (18) 19 (41) 19 (43) 25 ( Patients may find that an extended dosing regimen would still provide protection from bleeds but be easier to maintain. 
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